On October 24, 2019 Alligator Bioscience AB Interim Report January-September 2019(Press release, Alligator Bioscience, OCT 24, 2019, View Source [SID1234542456])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 substance to, with or without a new partner, bring ADC-1013 into Phase II clinical trials next year. In total, we now have three projects in clinical development, and soon another one where the first patient in Phase I will be dosed," commented CEO Per Norlén.
Significant events July-September
Alligator regains the global rights for the CD40 antibody ADC-1013 (mitazalimab) from Janssen.
Alligator continued its work on the clinical development plan for mitazalimab with the goal of starting a Phase II study in 2020.
Antibody agreement was signed with Biotheus Inc. of China, which obtained Chinese rights to an antibody from the antibody library ALLIGATOR-GOLD.
Events after the end of the period
ATOR-1015: The Phase I clinical trial is progressing well with seven dose levels evaluated for initial safety. Currently, doses of 100 mg, about 1.5 mg/kg, are given every two weeks.
ALG.APV-527: Along with co-development partner Aptevo, discussions are initiated with additional partners for the upcoming clinical development of ALG.APV-527 and, therefore, the submission of the application for permission to start clinical trial is delayed. For Alligator, this ensures that resources are available in order to bring the clinical portfolio forward with full force.
Financial information
July-September 2019
Net sales, SEK 4.3 million (0.2)
Total operating costs SEK -62.9 million (-40.6)
Operating result, SEK -58.5 million (-39.9)
Earnings per share before and after dilution, SEK -0.79 (-0.56)
Cash flow for the period, SEK -46.8 million (-39.7)
Cash, cash equivalents, incl securities, SEK 302.4 million (478.4)
January-September 2019
Net sales, SEK 4.4 million (1.4)
Total operating costs SEK -160.2 million (-125.5)
Operating result, SEK -155.2 million (-123.0)
Earnings per share before and after dilution, SEK -2.11 (-1.67)
Cash flow for the period, SEK -126.0 million (-70.0)
Read the complete report in the pdf below.
Conference call
All interested parties are invited to participate in a telephone conference, which will include a presentation of the Interim report. The event will be hosted by CEO Per Norlén and the presentation will be held in English.
When: 2:00 p.m. CEST Thursday 24, October 2019
Listen to the presentation: View Source
To participate in the telephone conference, please use the dial in details shown below:
SE: +46856642707
UK: +443333009262
US: +18335268381
The conference call will be made available on the company’s website after the call.
This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8:00 a.m. CEST on October 24, 2019.